Table 1 Registered COVID-19 Therapeutics and Vaccine Trials in Sub-Saharan Africa as of November 5, 2020
Country | Title | Interventions | Sponsor/Collaborators | Phase | Enrolment target | Enrolling Children < 18 years | Start date |
|---|---|---|---|---|---|---|---|
Ghana | PROTECT-Surg Preventing Pulmonary Complications in Surgical Patients at Risk of COVID-19 | Drug: Hydroxychloroquine Drug: Lopinavir/Ritonavir Drug: Hydroxychloroquine + Lopinavir/Ritonavir Drug: standard of care | National Institute of Health Research, UK | University for Development Studies School of Medicine and Health Sciences Tamale Teaching Hospital | Phase 3 | 6400 | Yes (≥16 years) | 25-Apr-20 |
Kenya South Africa | A study to determine if a new COVID-19 vaccine safely generates protective immune responses in adults in Kenya | Single dose of ChAdOx1 nCoV-19 vaccine vs Verorab (rabies vaccine) | University of Oxford KEMRI Wellcome Trust Program University of the Witwatersrand, Johannesburg | Phase 1/2 | 400 in Kenya 2000 (1950 HIV-uninfected and 50 people living with HIV) in South Africa | No | 28-Oct-20 in Kenya 24-Jun-20 in South Africa |
Nigeria | LACCTT Lagos COVID-19 Chloroquine Treatment Trial | Drug: Chloroquine phosphate Drug: Hydroxychloroquine sulphate | Lagos State Government Nigerian Institute of Medical Research | Not Applicable | 600 | No | 17-Apr-20 |
CRASH-19 Coronavirus Response - Active Support for Hospitalised COVID-19 Patients | Drug: Aspirin Drug: Losartan Drug: Simvastatin | London School of Hygiene and Tropical Medicine | Phase 3 | 1000 | No | 01-Apr-20 | |
IHP Detox tea trial Efficacy and safety of IHP Detox Tea for treatment of Corona virus disease 2019: a pilot placebo-controlled randomized trial | IHP Detox Tea (a special blend of Andrographis paniculata, Garcinia kola and Psidium guajava) | Neimeth International Pharmaceuticals Plc | Not Applicable | 72 | No | 01-May-20 | |
IVERCOVID Does ivermectin cure and/or prevent COVID-19? | Drug: ivermectin 6 mg Drug: ivermectin 12 mg Drug: placebo | Rachel Eye Center, Lagos University Teaching Hospital | Phase 3 | 45 | Yes (stated as ‘all ages’) | 23-Apr-20 | |
Senegal | SEN-CoV-Fadj Efficacy and Safety Evaluation of Treatment Regimens in Adult COVID-19 Patients in Senegal | Drug: Hydroxychloroquine Drug: Hydroxychloroquine + Azithromycin | Institut Pasteur de Dakar Fann Hospital, Senegal Ministry of Health, Senegal Diamniadio Children Hospital, Senegal Dalal Jamm Hospital, Senegal Epicentre, Paris, France | Phase 3 | 258 | Yes (≥15 years if married; ≥18 years if not married) | 01-Jun-20 |
ESHAZ Trial Hydroxychloroquine, Azithromycin and Zinc for the treatment of SARS-CoV-2 infection in Senegal | Drug: Hydrochloroquine 600 mg plus Azythromycin Drug: Hydrochloroquine 400 mg plus Azythromycin Drug: Zinc | Faculty of Medicine University Cheikh Anta Diop of Dakar Senegal. | Phase 3 | 384 | No | 01-Jun-20 | |
South Africa | CQOTE Chloroquine Outpatient Treatment Evaluation for HIV-COVID-19 | Drug: Chloroquine or hydroxychloroquine | University of Cape Town | Phase 3 | 560 | No | 01-May-20 |
BCG Vaccination for Healthcare Workers in COVID-19 Pandemic | Biological: Bacille Calmette-Guerin (BCG) Other: Placebo Comparator | TASK Applied Science (University of Cape Town) | Phase 3 | 500 | No | 04-May-20 | |
Sudan | GA & COVID19 Potential Role of Gum Arabic as Immunomodulatory Agent Among COVID 19 Patients | Dietary Supplement: Acacia Senegal Dietary Supplement: Pectin | Al-Neelain University University of Khartoum | Phase 2 Phase 3 | 110 | Yes (≥5 to 90 years) | 01-Jun-20 |
Kenya South Africa | SOLIDARITY Public health emergency SOLIDARITY trial of treatments for COVID-19 infection in hospitalized patients | 1. Local standard of care alone OR local standard of care plus one of 2. Remdesivir 3. Chloroquine or hydroxychloroquine 4. Lopinavir + ritonavir 5. Lopinavir + ritonavir plus interferon-beta | World Health Organization | Phase 3 | 10,000 | No | 01-Mar-20 |
Cameroon Ghana Uganda South Africa Zambia Zimbabwe | CROWN CORONATION: Chloroquine RepurpOsing to healthWorkers for Novel CORONAvirus mitigaTION | Drug: Low-dose chloroquine/hydroxychloroquine Drug: Mid dose chloroquine or hydroxychloroquine Drug: High dose chloroquine or hydroxychloroquine Drug: Placebo | Washington University School of Medicine/Bill and Melinda Gates Foundation | Phase 3 | 55,000 | No | 01-Apr-20 |
Madagascar | Efficacy of New COVID 19 Treatment | Efficacy of Artesunate IV alone or combined with vitamin C IV for the treatment of COVID-19 | Ministry of Health, Madagascar | Phase 2 | No | 29-Apr-20 | |
South Africa | ENSEMBLE Ad26.COV2.S1 for the Prevention of SARS-CoV-2-Mediated COVID-19 in Adult Participants | Biological: Ad26.COV2.S1 Other: Placebo | Janssen Pharmaceutical Companies University of the Witwatersrand, Johannesburg | Phase 1/2 | 6000 from Argentina, Brazil, Chile, Columbia, Mexico, Peru, Philippines, USA, Ukraine and South Africa | No | 2-Nov-20 |
South Africa | Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals | Biological: BNT162b1 Biological: BNT162b2 Other: Placebo | Pfizer and Biontech | Phase 2/3 | 11,000 from U.S., Argentina and Brazil, Germany, Turkey and South Africa | No | No date |
South Africa | Safety and Immunogenicity of a SARS-CoV-2 rS Nanoparticle Vaccine With/Without Matrix-M Adjuvant | NVX-CoV2373 | Novavax Coalition for Epidemic Preparedness Innovations University of the Witwatersrand, Johannesburg | Phase 2 | 2904 (2650 HIV-uninfected and 240 people living with HIV) | No | 17-Aug-20 |